Article
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
Science translational medicine - 31 Jul 2013
Corcoran Ryan B, Rothenberg Stephen Michael, Hata Aaron N, Faber Anthony C, Piris Adriano, Nazarian Rosalynn M, Brown Ronald D, Godfrey Jason T, Winokur Daniel, Walsh John, Mino-Kenudson Mari, Maheswaran Shyamala, Settleman Jeffrey, Wargo Jennifer A, Flaherty Keith T, Haber Daniel A, Engelman Jeffrey A
Abstract excerpt
RAF and MEK (mitogen-activated or extracellular signal-regulated protein kinase kinase) inhibitors are effective in treating patients with BRAF-mutant melanoma. However, most responses are partial and short-lived, and many patients fail to respond at all. We found that suppression of TORC1 activity in response to RAF or MEK inhibitors, as measured by decreased phosphorylation of ribosomal protein S6 (P-S6),...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.